SCI's 21.5% Bullish Update: Why UBS' Raise Still Points to a Quality Defensive

UBS' $105 target keeps the focus on durability, not excitement

UBS made the setup harder to ignore. The firm kept its Buy rating and raised its target to $105.00, implying 21.55% upside. That matters because the upgrade arrives alongside a quarter that still looks soft at first glance, while Street expectations remain modest enough to keep the debate alive.

The real question is straightforward: do you pay for a defensive business while near-term numbers look tame, or wait and risk missing the move if the market decides quality deserves a higher multiple again? With SCI trading in the mid-$80s, this is less a theoretical debate than a timing decision.

Low expectations point to steadiness, not a booming story

The cautious case has some fuel. Wall Street is still working off only a $4.130 fiscal 2026 EPS estimate, so investors are not being asked to buy into explosive growth. They are being asked to trust consistency. That leaves less room for disappointment, but a low bar is not the same thing as a broken business.

UBS' update still points to a resilient model: local presence, repeated demand, and steady execution matter more here than financial engineering. That is why the raise looks more like a vote for a quality defensive than a turnaround narrative.

SCI's soft quarter looked worse than the underlying business

The operating question after the release was not whether the quarter looked weak. It did. The more important question was whether this was a rough patch or the start of a weaker business.

Funeral volumes softened, but the reasons mattered

The bad news was real: core funeral volumes declined 6.6%. That is something investors should notice. But management attributed the decline to a strong prior-year flu season and broader mortality trends, not to fading relevance. Comparison pressure can hit a reported number without doing lasting damage to the business.

Other parts of the operation held up better. Cemetery revenue grew 7%, helped by a 10% increase in preneed sales production. That also included $20 million in year-over-year growth from large sales exceeding $100,000. In plain English, demand did not disappear. Preneed purchases continued, and larger policies kept selling. That is the kind of front-loaded demand profile investors usually want in a defensive name.

Pricing and cost control kept the pressure manageable

SCI also did the basic things well. Average revenue per funeral service increased 3.5%, suggesting pricing held up better than traffic. Fixed cost growth stayed at just over 1%. When pricing remains firm and cost growth stays muted, the income statement can absorb a volume dip without major damage.

There were also two practical operating improvements:

• Preneed funeral sales momentum improved after an insurance partner transition and the rollout of insurance products to all SCI Direct locations.
• Cemetery sales velocity increased for the fifth consecutive quarter, supported by seminars and better lead-to-sale ratios.

Those are not flashy metrics, but they matter. They suggest management is still working the business at the local level.

What to watch in the next two quarters

The main issue is whether the comparison problem fades. Management is still assuming funeral volume declines moderate to between 1% and 3% for the full year, and it expects comparisons to improve in the second half of 2026.

Watch the next two quarters on three items:

• Does the funeral volume gap narrow as guided?
• Do cemetery sales trends keep improving?
• Do cost pressures stay contained enough to protect margins?

If those signals hold, this quarter looks more like a soft period than a structural break.

SCI valuation leaves room for both patience and conviction

That leaves the decision in investors' hands: pay a little extra for a business that still looks durable, or wait for the next report to confirm the story is intact.

The multiple is not cheap, but it is not extreme for the profile

The analyst spread shows where the debate sits. Oppenheimer recently lifted its target to $97.00, while JPMorgan set a $100.00 target. Both are constructive, but neither implies heroic upside. That reinforces the idea that Wall Street sees a quality company more than a recovery trade.

A simple way to think about the setup

For cautious investors, the cleaner approach is to wait for proof, not promises. The key checks are straightforward:

• The business handles soft funeral demand without losing pricing discipline.
• Cemetery trends continue to support the mix.
• Cash generation remains solid enough to support the dividend and the multiple.

If that happens, the stock can move higher on confidence alone. If it does not, the multiple can compress quickly because investors are not buying SCI for fast growth.

What would weaken the case

• Another weak quarter instead of stabilization.
• Evidence the business is discounting to keep customers.
• Cash flow that no longer supports the current multiple.

If you prefer confirmation, waiting is reasonable. If you already value steady defenders, a starter position is defensible, but not because the stock is obviously cheap. It is reasonable because durable businesses often become rarer, not cheaper, in weak markets.